Monday, December 23, 2024
HomeTagsClinical Development Plans

Clinical Development Plans

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis ("MS"),...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics